61 drugs found substandard in 19 pharmaceutical industries in Himachal

Nalagarh:  As many as 24 medicines, syrups and injections manufactured in 19 pharmaceutical industries in Himachal Pradesh have been found to be substandard in a probe conducted by the Central Drugs Standard Control Organisation (CDSCO). Medicines that have not met the quality scale.

According to the information, they include medicines used in the treatment of pain including fungal infections, cancer, type 2 diabetes, severe bacterial infections, cardiac arrest, antibiotics, respiratory diseases, anti-inflammatory drugs, angina, Alzheimer’s, antiparasitic, stomach ulcers, fever.

These medicines have been manufactured in pharmaceutical industries located in Baddi, Barotiwala, Waknaghat, Paonta Sahib. Five samples from the Baddi-based Effi Pharma industry have failed. The state drug control authority has already taken action against this industry and banned the production of the drug.

In the drug alert issued by the CDSCO for the month of October, 37 drugs manufactured in New Delhi, Jammu, Rajasthan, Bihar Uttarakhand, Bengaluru, Kolkata, Uttar Pradesh, Punjab, Rajasthan, Gujarat, Maharashtra, Chennai have also been found to be substandard.

The State Drug Controller has issued notices to all the pharmaceutical companies involved in the drug alert and has issued instructions to immediately recall the entire batch of the concerned drug from the market. Along with this, assistant drug controllers have been instructed to jointly inspect all pharmaceutical industries and submit a detailed investigation report.

Meanwhile, State Drug Controller Navneet Marwah said that show-cause notices have been issued to all the concerned pharmaceutical companies involved in the drug alert for the month of October issued by the CDSCO and instructions have been given to recall the entire stock of the concerned batch. Apart from this, strict action will be taken against those industries whose samples are failing repeatedly.

Related Posts

  • Pharma
  • July 26, 2024
  • 128 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 125 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD